Small-cell lung cancer: treatment progress and prospects

Area of Science:

• Oncology
• Pulmonology
• Medical Oncology

Background:

• Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer, accounting for a significant proportion of lung cancer deaths.
• Despite advances, SCLC remains challenging to treat, with limited effective therapeutic options for advanced or relapsed disease.

Purpose of the Study:

• To review current and emerging treatment strategies for small-cell lung cancer.
• To evaluate the efficacy of different chemotherapy regimens, novel agents, radiotherapy, and surgical interventions in SCLC management.

Main Methods:

• Review of existing literature on SCLC treatment protocols.
• Analysis of clinical trial data for first-line therapies (PE, CAV), dose intensity, and novel agents (gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan).
• Assessment of the role of thoracic radiotherapy, prophylactic cranial irradiation, and surgical resection in specific SCLC scenarios.

Main Results:

• Platinum plus etoposide (PE) or cyclophosphamide, Adriamycin, and vincristine (CAV) are reasonable first-line therapies; alternating regimens offer no significant advantage.
• Increasing dose intensity does not improve survival and should be reserved for clinical trials.
• Novel agents show promise, and enrollment in clinical trials is encouraged for patients with extensive disease due to poor prognosis in relapsed cases. Thoracic radiotherapy offers a survival benefit in limited-stage SCLC, and prophylactic cranial irradiation reduces CNS recurrences.
• Surgery is indicated for solitary pulmonary nodules (with adjuvant chemotherapy) or unresponsive chest tumors potentially harboring non-small-cell lung cancer.

Conclusions:

• Combination chemotherapy remains the cornerstone of SCLC treatment, with PE and CAV as standard first-line options.
• Emerging agents and clinical trial participation are crucial for improving outcomes in relapsed or extensive-stage SCLC.
• Radiotherapy and selective surgical approaches have specific roles in managing limited-stage and localized SCLC, respectively.